Paclitaxel may represent a possible new treatment option for primary cardiac angiosarcoma, though the observed response was transient.
Transient paclitaxel response in one case is hypothesis-generating; does not support routine use in primary cardiac angiosarcoma.
CASTILLA E., PASCUAL I., RONCALÉS F., AGUIRRE E. & RÍO A. DEL (2010) European Journal of Cancer Care19, 699–700 Transient response of cardiac angiosarcoma to paclitaxel Malignant tumours of the heart are a group of tumours with low incidence but very high mortality. Delays in diagnosis are common because of their multiple forms of presentation, and 80% present with metastases, further reducing the possibility for cure. We present here the case of a patient with primary cardiac angiosarcoma that highlights the misdiagnosis at clinical presentation, current diagnostic modalities and a possible new treatment using paclitaxel for cardiac angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Castilla et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: